Fiori Timothy C 4

What Happened
Timothy C. Fiori, Chief Financial Officer of Immucell Corp (ICCC), received a grant of options covering 120,000 shares on 2026-01-27. The Form 4 reports the transaction as a derivative award (code A) with a reported transaction price of $0.00 (this reflects an option grant; it does not indicate the economic value or exercise price of the options). The filing footnote states the grant will be treated as an incentive stock option (ISO) to the maximum extent allowed by the Internal Revenue Code, with any remainder treated as nonqualified stock options (NQSOs).

Key Details

• Transaction date: 2026-01-27; Form 4 filed: 2026-01-29 (timely filing under Section 16).
• Award: 120,000 stock options (derivative grant); transaction price reported as $0.00 on the Form 4.
• Vesting: 40,000 options vest on each of the first, second and third anniversaries of the grant date (per footnote).
• Tax/treatment note: Options will be treated as ISOs to the extent permitted by tax rules; the balance will be NQSOs.
• Shares owned after transaction: not specified in the provided filing.

Context
This is an option grant (an award), not an open-market purchase or sale. Options typically vest over time and require exercise (often at a specified strike price) to convert to shares; the Form 4 does not disclose the exercise/strike price or the grant’s fair-market value, so you cannot determine immediate in-the-money value from this filing alone. Grants like this are common as long-term incentive compensation rather than an immediate buy/sell signal.